Table 4.

Median (25th, 75th percentiles) model-predicted values of the area under the concentration-time curve over a dosing interval for each drug in blood plasma and the estimated unbound drug area under the plasma concentration-time curve in blood plasma cervicovaginal fluid, at both first dose and multiple doses

	BP AUCτ (μg•h/L)	BP fAUCτ (μg•h/L)	CVF AUCτ (μg•h/L)	CVF AUCτ:BP AUCτ ratio	CVF AUCτ:BP fAUCτ ratio
Efavirenz
First dose	24.5 (16.1, 30.3)	0.245 (0.161, 0.303)	0.0127 (0.0746, 0.193)	0.00527 (0.00298, 0.0128)	0.527 (0.298, 1.28)
Multiple dose	46.7 (33.9, 106)	0.470 (0.339, 1.06)	0.262 (0.110, 0.579)	0.00655 (0.0125, 0.000744)	0.655 (0.0744, 1.25)
Atazanavir
First dose	25.3 (6.19, 43.9)	3.55 (0.867, 6.15)	5.66 (8.36, 2.12)	0.299 (0.0846, 1.55)	2.14 (0.604, 11.1)
Multiple dose	54.6 (11.5, 68.1)	7.64 (1.61, 9.54)	5.53 (3.18, 11.4)	0.173 (0.0719, 0.596)	1.24 (0.514, 1.24)
Lamivudine 150 mg twice daily
First dose	3.86 (3.58, 4.20)	2.31 (2.15, 2.52)	10.0 (6.07, 48.9)	2.77 (1.35, 1.62)	4.62 (2.24, 27.0)
Multiple dose	3.17 (2.71, 5.47)	1.90 (1.62, 3.28)	27.7 (14.5, 59.2)	5.92 (4.29, 19.5)	9.86 (7.15, 32.5)
Lamivudine 300 mg once daily
First dose	10.1 (9.49, 13.6)	6.06 (5.70, 8.15)	62.2 (10.4, 287)	5.40 (0.976, 30.6)	8.98 (1.63, 51.0)
Multiple dose	12.9 (4.35, 17.9)	7.73 (2.61, 10.7)	36.1 (0.526, 99.2)	2.81 (0.53, 9.97)	4.67 (0.878, 16.6)
Tenofovir
First dose	2.56 (1.71, 4.68)	2.38 (1.59, 4.35)	4.18 (7.30, 18.1)	1.57 (0.132, 13.7)	1.68 (0.141, 14.7)
Multiple dose	2.32 (1.21, 4.08)	2.16 (1.13, 3.79)	4.56 (1.78, 10.6)	1.52 (0.722, 7.40)	1.64 (0.776, 7.95)

Ratios for CVF AUC_τ:BP AUC_τ and CVF AUC_τ:BP fAUC_τ are provided as median (25th, 75th percentiles) for each drug at each sampling visit

AUC_τ area under the plasma concentration-time curve during the dosing interval, BP blood plasma, CVF cervicovaginal fluid, fAUC_τ unbound drug area under the plasma concentration-time curve in BP